The present disclosure generally relates to devices and methods for removing acute blockages from blood vessels during intravascular medical treatments. More specifically, the present disclosure relates to a clot retrieval device for removing a clot from a blood vessel.
This disclosure relates to devices and methods of removing acute blockages from blood vessels. Acute obstructions may include a clot, misplaced devices, migrated devices, large emboli, and the like. Thromboembolism occurs when part or all of a thrombus breaks away from the blood vessel wall. This clot (now called an embolus) is then carried in the direction of blood flow. An ischemic stroke may result if the clot lodges in the cerebral vasculature. A pulmonary embolism may result if the clot originates in the venous system or in the right side of the heart and lodges in a pulmonary artery or branch thereof. Clots may also develop and block vessels locally without being released in the form of an embolus, and this mechanism is common in the formation of coronary blockages. The devices and methods herein are particularly suited to removing clot from cerebral arteries in patients suffering acute ischemic stroke (AIS), from pulmonary arteries in patients suffering from pulmonary embolism (PE), from coronary native or graft vessels in patients suffering from myocardial infarction (MI), and from other peripheral arterial and venous vessels in which clot is causing an occlusion.
There are a number of access challenges that can make it difficult to deliver devices to a target site. In cases where access involves navigating the aortic arch (such as coronary or cerebral blockages) the configuration of the arch in some patients makes it difficult to position a guide catheter. The tortuosity challenge is even more severe in the arteries approaching the brain. It is not unusual at the distal end of the internal carotid artery that the device will have to navigate a vessel segment with several extreme bends in quick succession over only a few centimeters of travel. In the case of pulmonary embolisms, access may be gained through the venous system and then through the right atrium and ventricle of the heart. The right ventricular outflow tract and pulmonary arteries are delicate vessels that can easily be damaged by inflexible or high-profile devices. For these reasons it is desirable that a clot retrieval device be compatible with as low profile and flexible access and support catheters as possible.
The vasculature in the area in which the clot may be lodged is often fragile and delicate. For example, neurovascular vessels are more fragile than similarly sized vessels in other parts of the body and are located in a soft tissue bed. Excessive tensile forces applied on these vessels can result in perforations and hemorrhage. Pulmonary vessels are larger than those of the cerebral vasculature, but are also delicate in nature, particularly more distal vessels.
Stent-like clot retrieval devices are being increasingly used to remove a clot from cerebral vessels of acute stroke patients. These devices often rely on a pinning mechanism to grab the clot by trapping it between the self-expanding stent-like body and the vessel wall. This approach has a number of disadvantages.
A stent-like clot retriever depends on its outward radial force to retain its grip on the clot. This compressive force will tend to dehydrate the clot, which in turn can increase its coefficient of friction, making it more difficult to dislodge and remove from the vessel. If the radial force is too low the stent-like clot retriever will lose its grip on the clot, but if the radial force is too high the stent-like clot retriever may damage the vessel wall and require too much force to withdraw. Therefore stent-like clot retrievers that have sufficient radial force to deal with all clot types may cause vessel trauma and serious patient injury, and stent-like clot retrievers that have appropriate radial force to remain atraumatic may not be able to effectively handle clot types in all thrombectomy situations. Pinning the clot between the stent-like clot retriever and the vessel wall also results in high shear forces against the side of the clot as it is removed, potentially releasing fragments of the clot. If these fragments are not retained by the device, they may be released leading to further blockages in the distal vasculature.
Certain conventional stent-like clot retriever designs also do not retain their expanded shape very well when placed in tension in vessel bends, due to the manner in which their strut elements are connected to one another which results in the struts being placed in tension during retraction. This tension is due to friction between the device and the blood vessel and is increased if an additional load is applied load such as the resistance provided by a clot. This can result in a loss of grip on the clot as the stent-like clot retriever is withdrawn proximally around a bend in a tortuous vessel, with the potential for the captured clot to escape. In a bend, the struts on the outside of the bend are placed in higher tension than those on the inside. In order to attain the lowest possible energy state, the outside surface of the clot retrieval device moves towards the inside surface of the bend, which reduces the tension in the struts, but also reduces the expanded diameter of the device.
Furthermore, when attempting to remove long clots, a conventional device that is shorter than the clot is unlikely to be able to restore flow through the occluded area upon deployment. As a result, the pressure gradient across the clot remains a significant impediment to its removal. Simply making such a device longer would likely render it difficult to track through tortuous anatomies and can be traumatic to the vasculature, taking more force to withdraw and potentially getting the device stuck, requiring surgery to remove.
In seeking procedural efficiency, devices with multiple bodies have also been used. Such devices can have an outer body capable of scaffolding a target vessel and an inner body for embedding and capturing a clot. These devices can perform well in engaging with and dislodging a clot but having a larger and often stiffer network of struts can potentially make it more difficult to retract the device and partially or fully re-sheath it within an outer catheter. Compression of the members of the outer body during this process can possibly interfere with or even loosen the grip of the inner body on a captured clot, especially for longer clots or in situations where grip is maintained between through a pinching action with the device and the distal tip of the outer catheter. The larger expanded shape of the outer body can result in the outer body struts impinging on or deflecting those of the inner body as the device is partially or fully collapsed during retraction.
The effectiveness of a given device is also important as, for many reasons, it is often necessary for a physician to make multiple passes in order to fully remove an obstruction Each time a clot retrieval device is withdrawn the access to the target site is lost. Thus, it can be necessary to re-advance a guidewire and microcatheter to access and re-cross the clot, and then remove the guidewire and advance the clot retrieval device through the microcatheter. Navigating the guidewire and microcatheter to the clot can take a considerable amount of time especially if the vessels are tortuous. The additional time and device manipulation add to the risks of complication to which the patient is exposed, highlighting the importance of effective and efficient devices.
The challenges described above need to be overcome for any device to provide a high level of success in removing a clot, restoring flow, and facilitating good patient outcomes. The present designs are aimed at providing an improved clot retrieval device to address the above-stated deficiencies.
The designs herein can be for a clot retrieval device for removing clot from a body vessel. The device can have a framework of struts forming an elongate inner body with a proximal end, a distal end, and a longitudinal axis. The elongate inner body can be divided into one or more sections extending distally from a proximal shaft used to manipulate the device. A proximal section can have a clot pinching structure with a collapsed delivery configuration when constrained within an outer catheter, an expanded clot engaging configuration when deployed at a target site, and a clot pinching configuration where the pinching structure is at least partially constrained. As the device transitions from the engaging deployed configuration, the clot pinching structure can be configured to pinch and grasp the clot when in the clot pinching configuration.
The clot pinching structure can take a variety of forms, such as a flat pattern arranged in an undulating or spiral fashion. In one example, the pinching structure contains an array of adjacent segments. The segments can be sections of low strut density bordered by rings of higher density, or otherwise vary in shape at different longitudinal positions such that the radial force extorted in a clot by at least two adjacent segments differs from each other. In another example, the pinching structure can have a series of clot-receiving cells. The cells can consist of one or more flexible struts extending between crowns such that the cells are capable of constricting portions of a clot in the cells when the struts are in compression. These patterns allows a microcatheter or outer catheter to be advanced over the proximal end of the pinching structure in order to compress and grip a clot between the tip of the catheter and at least a portion of the struts of the pinching structure as the device is transitioned from the expanded deployed configuration to the partially-constrained clot pinching configuration.
A more distal section of the elongate inner body of the device can be a porous inner channel which can be fixedly connected to the distal end of the clot pinching structure. The inner channel can include a tubular main body composed of a plurality of struts defining inner body closed cells around the longitudinal axis. The cells and struts can be designed to penetrate the clot and exert a radial force to create a lumen through the clot and restore flow on deployment to a radially expanded configuration. The cells can also allow portions of the clot to escape compression by displacing through the cell openings, thereby reducing the radial force exerted on the vessel walls to minimize vessel trauma and reduce tensile disturbance of the distal vascular bed.
The device can have dual expandable members whereby the properties of the inner and outer members may be tailored independently of each other. In one example, an outer cage is supplied with the inner elongate body. The outer cage can be coaxial with the inner elongate member or can be radially offset. The outer cage can be expandable to a greater extent than the inner elongate body and configured to appose with and support the walls of a target vessel. The inner elongate body can be arranged substantially within the lumen of the outer cage. The difference in radial expansion between the inner body and outer cage can define a reception space between the two into which a clot can be received.
Similar to the inner elongate member, the outer cage can also have one or more sections. The cage can have a proximal first scaffolding segment with a framework of struts forming one or more proximal expandable bodies arranged longitudinally. The proximal expandable bodies can be made of non-circumferential closed cells forming one or more support arms spaced around the longitudinal axis so that large circumferential gaps exist between adjacent arms. For example, the first scaffolding segment of the outer cage can have two support arms diametrically opposed and spaced 180 degrees apart.
The outer cage can also have a distal second scaffolding segment with a framework of struts forming one or more distal expandable bodies arranged longitudinally. Similar to the first scaffolding segment, the second scaffolding segment can have a network of closed cells around the longitudinal axis. The cells of the distal expandable bodies of the second scaffolding segment can be fully circumferential so as to support the vessel at all clocking positions. The distal section of the elongate inner body, the porous inner channel, can be disposed within the lumen of the second scaffolding segment.
The closed cells of the first and second scaffolding segments of the outer cage can be larger than the cells of the inner body. As a result, the outer cage can be configured to be expanded within an occlusive clot in a blood vessel so that the cage allows the clot to migrate into the reception space within as the cage expands.
For increased device flexibility, the expandable bodies of the first and second scaffolding segments can be hingedly connected to each other so they can flex independently as the device is advanced or retracted through bends in the vasculature. Additionally, the cells of each expandable body of the first and second scaffolding segment can have struts forming at least one distal apex free from connection to an adjacent closed cell.
In another example, the clot retrieval device can have a dual layer setup with an inner elongate body disposed within a porous outer body. The inner elongate body can have a proximal clot engaging element having a constrained delivery configuration, an expanded clot engaging deployed configuration, and an at least partially constrained clot pinching configuration. Distal to the clot engaging element can be a tubular inner channel having a constrained delivery configuration and an expanded deployed configuration. When expanded, the tubular inner channel can utilize radial force to restore the flow of blood in an occluded vessel.
The clot engaging element can have a framework of struts configured to exert an outward radial force on a clot when expanded to the deployed configuration. The outward force can vary in amplitude along the length of the clot engaging element. In one case, the radial force follows a generally sinusoidal waveform pattern. The amplitude of the waveform pattern can be generally equal across peaks, or it can be different at the proximal or distal end for a firmer grip on portions of the clot. The amplitude of the peaks, for example, can decrease along the length of the clot engagement element so that it is higher at the proximal end and lower at the distal end.
The device can also have a longitudinal axis extending centrally through the proximal clot engaging element and distal tubular inner channel. The struts of the clot engaging element can be a flat pattern or planar so that when deployed to an expanded state the pattern aligns with or around the axis. In one example, the struts of the element can form a planar pattern that is twisted around the axis in a spiral or helical shape. In a separate example, the struts can form a plurality of adjacent segments with regions of high and low strut density, or longitudinal asymmetry such that the radial force exerted by two adjacent segments is different from each other to maintain better grip on a clot. In an additional case, adjacent struts of the clot engaging element can have bends or twists in the same or different direction to change the radial force so that a captured clot is compressed and pinched when the clot engaging element is moved to the clot pinching configuration.
Disposed around the inner elongate body in the dual layer device setup can be porous outer body with a non-circumferential proximal segment and a fully circumferential distal segment connected to the proximal segment. The outer body can be designed so that it expands to a radial extent greater than the radial expansion of the inner elongate body when the device is deployed from a delivery catheter. When folded inside the catheter, the outer body can have a radial size equal to or greater than that of the inner body.
The proximal segment and the distal segment of the porous outer body can each have one or more expandable bodies. The expandable bodies can each have a plurality of struts forming closed cells. The cells are generally larger than, for example, cells of the inner elongate body so that the expandable outer body can exert radial force on a clot and the target vessel while providing scaffolding that will not obstruct a clot from passing through and being captured by the inner body. Each expandable body of the proximal and distal segments can have struts join together in at least one distal apex that is free from connection with another adjacent closed cell, enhancing flexibility by allowing each body to flex and react to localized forces independently. Other portions of the expandable bodies can have regions of convergence where struts intersect with intermediate coupling struts or connecting arms joining adjacent bodies.
The embolization risk during clot retrieval with the device can be reduced by providing a distal fragment protection element appended to one or both of the inner elongate member or the outer cage. The protection element can consist of a net or scaffolding zone across the vessel lumen towards the distal end of the device. The element can be three dimensional in that it has depth as well as surface area. In other cases, fibers or fine wires can be utilized to provide added scaffolding in the element with minimal impact on device profile or deliverability. Combining a fragment protection element with the scaffolding of both the inner and outer members provides a more effective filter than utilizing one member alone
In one example, the distal portion of the inner elongate body can have a plurality of struts which are configured as a fragment protection element in a volumetric pattern around the longitudinal axis. The distal portion of the inner elongate body can also have a bulged or flared framework of struts.
In an alternative example, the fragment protection element can be connected to or be a part of the distal end portion of the outer cage or member. The end of the outer cage can also taper through a series of distal crown struts. The crown struts of the outer member can be configured in a generally conical shape so that the outer member necks down distally as a natural barrier around the protection element. The struts can also cross over circumferentially to occupy more cross-sectional area or have strands in a mesh or braid for increased coverage.
A method for using the clot retrieval device to extract an occlusive clot from a vessel can include the step of providing an outer catheter having a tubular body and a collar at its distal end. Also provided can be a clot retrieval device with an elongate shaft mated to an expandable element capable of transitioning from a collapsed delivery configuration to an expanded deployed configuration. The clot retrieval device can have an inner body with a proximal clot pinching element connected to a more distal flow channel element. Arranged around the inner body can be an outer body with a non-circumferential first scaffolding section joined to a fully circumferential second scaffolding section. The second scaffolding section can have a pivoting or hinge-like connection to the first scaffolding section to allow the device to conform to sharp bends in the vasculature.
The method can involve delivering the clot retrieval device to the target occlusion in the collapsed configuration, such as when it is folded or constrained within a microcatheter. The microcatheter can be directed to the target site through a guide catheter or intermediate catheter using a guidewire or other commonly known technique in the art. The microcatheter can be forwarded across a clot and then withdrawn to expose the clot retrieval device and allow it to expand within the clot. The gaps in the non-circumferential first scaffolding section can allow at least a portion of the clot to exposed to the inner clot pinching element. Similarly, the radial force from the expansion of the fully circumferential second scaffolding section can displace portions of the clot through large outer cells so that the clot is engaged with the flow channel element. Expansion of the flow channel element can open a path to at least partially restore the flow of blood to recanalize the vessel.
To continue the method for removing the clot, the position of the clot retrieval device can be rigidly maintained while the outer catheter is advanced along the elongate shaft so that the collar of the outer catheter engages with the expandable element to pinch at least part of the clot in compression between the collar and the pinching element. Once the user feels resistance indicating that the clot has been pinched and grip is maintained, the outer catheter can be removed from the vessel in unison with the clot retrieval device and captured clot while maintaining the relative positions so the collar remains engaged with the expandable element of the clot retrieval device. The clot retrieval device and pinched clot can then be fully removed from the patient.
In many cases, after retrieving some or all of the occlusive clot, contrast media can be injected through the outer catheter to allow a more thorough assessment of the degree to which the vessel is patent. Additional passes with the thrombectomy device can be made if an obstruction remains in the vessel. Any remaining devices can then be removed from the patient once adequate recanalization of the target vessel is observed. The devices of the present disclosure provide a means to minimize the number of catheter advancements required to treat a patient, thereby reducing the likelihood of vessel damage and the associated risk of vessel dissection in cases where multiple passes are required.
Other aspects and features of the present disclosure will become apparent to those of ordinary skill in the art, upon reviewing the following detailed description in conjunction with the accompanying figures.
The above and further aspects of this invention are further discussed with reference to the following description in conjunction with the accompanying drawings, where like reference numbers indicate elements which are functionally similar or identical. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating principles of the invention. The figures depict one or more implementations of the inventive devices, by way of example only, not by way of limitation.
The objective of the disclosed designs is to create a clot retrieval device capable of providing more effective and efficient removal of obstructions in the vasculature while maintaining a high level of deliverability and flexibility during procedures. The designs can have an outer expandable member within which runs an inner expandable member. The disclosed devices share a common theme of dual layer construction where the inner member has a clot pinching capture capability and minimal interference in this capability from the outer member. Both members can be directly or indirectly connected to an elongate shaft, and a distal net or scaffold configured at the distal end of the device can prevent the escape of clot fragments. This distal net may be appended to either the shaft, the inner or the outer members, or to multiple of these.
This dual layer construction is intended to allow a clot to enter through the large openings or gaps in the outer expandable member and reside in the reception space provided between the two expandable members. At least a portion of the inner member can have a denser scaffold than that of the outer member such that the clot is prevented from entering its lumen, creating a flow channel across the clot once the device is deployed across it.
Both the inner and outer expandable members are desirably made from a material capable of recovering its shape automatically once released from a highly strained delivery configuration. The material can be in many forms such as wire, strip, sheet, or tube. A suitable manufacturing process can be to laser cut a Nitinol tube and then heat set and electropolish the resultant structure to create a framework of struts and connecting elements. A range of designs are envisaged for each of these elements as described, and it is intended that any of these elements can be used in conjunction with any other element, although to avoid repetition they are not shown in every possible combination.
Specific examples of the present invention are now described in detail with reference to the Figures. While the description is in many cases in the context of mechanical thrombectomy treatments, the designs may be adapted for other procedures and in other body passageways as well.
Accessing the various vessels within the vasculature to reach a clot, whether they are coronary, pulmonary, or cerebral, involves well-known procedural steps and the use of a number of conventional, commercially available accessory products. These products, such as angiographic materials, rotating hemostasis valves, delivery access catheters, and guidewires are widely used in laboratory and medical procedures. When these or similar products are employed in conjunction with the disclosure of this invention in the description below, their function and exact constitution are not described in detail.
Referring to
The inner and outer members are preferably made of a super-elastic or pseudo-elastic material such as Nitinol or another such alloy with a high recoverable strain. Shaft 6 may be a tapered wire shaft, and may be made of stainless steel, MP35N, Nitinol or other material of a suitably high modulus and tensile strength. Shaft 6 and device 100 can have indicator bands or markers to indicate to the user when the distal end of the device is approaching the end of the microcatheter during insertion or mark the terminal ends of the device during a procedure. These indicator bands can be formed by printing, removing, or masking areas of the shaft for coating, or a radiopaque element visible under fluoroscopy, so that they are visually differentiated from the remainder of the shaft.
The shaft 6 may be coated with a material or have a polymeric jacket to reduce friction and thrombogenicity. The coating or jacket may consist of a polymer, a low friction lubricant such as silicon, or a hydrophilic/hydrophobic coating. This coating can also be applied to the outer cage 210 and elongate inner body 110.
A dual-layer, multi-diameter device 100 as shown in various figures throughout this disclosure has several advantages. The inner body 110 with a smaller radial size can embed firmly in a target clot for a secure grip with a steep opening angle, while the larger radial size of the outer cage 210 can remain in contact with and appose the vessel walls and protect against distal migration of the clot as the device is retracted proximally into progressively larger diameter vessels.
A top view of the compound device 100 with dual inner and outer expandable members of
The elongate inner body can have multiple regions to provide both a strong grip on a clot and a strong opening force to create a lumen to restore flow on deployment. The elongate inner body 110 can have a proximal clot pinching section 120 which can provide a strong grip on the clot for the critical initial step of disengaging the clot from the vessel, enabling the outer cage 210 to be configured with a low radial force.
A distal section of the elongate inner body 110 can be a porous inner channel 130 configured to create a flow lumen through at least a portion of the clot. This flow lumen can reduce the pressure gradient across the clot, making it easier to dislodge and remove. The porous inner channel 130 can be a tubular shape and have a diameter when expanded that may be tailored so as to reduce the risk of a reperfusion injury. The restricted blood flow through the lumen can ensure that the pressure applied to blood vessels immediately after flow restoration is lower than normal thereby reducing the risk of bleeding in the vascular bed. Full perfusion can be subsequently restored by removing the device and the captured clot.
The outer cage member 210 can be a plurality of struts forming expandable bodies configured to self-expand upon release from a restraining sheath (such as a microcatheter) to a diameter larger than the radial size of the inner body 110, as shown in
The proximal portion of the outer cage 210 can have expandable bodies 216 with cells which are not completely circumferential around the device. providing a level of scaffolding that is less than that of the distal expandable bodies 217. Portions of a clot can pass into the gaps between the cells and support arms 222 of the proximal expandable bodies 216 so they are engaged by clot pinching structure 120. Having cells in the proximal expandable bodies 216 which are not completely circumferential can result in a lower surface contact area and a radial force which allows the clot to more easily protrude into the gaps in this section of the device. When the device is withdrawn into an outer catheter, the clot pinching structure 120 can maintain a secure grip on the clot without interfering impingement from the struts of the arms 222 of the outer cage 210. Support arms 222 can also have bends or crowns which would bias movement away from, or at least not in the same direction as, the clot pinching element so that the support arms do not shear portions of the clot when the proximal portion of the device is partially constrained by an outer catheter.
The proximal expandable body or bodies 216 can be connected to the most proximal body of the distal expandable bodies 217 by coupling struts 233. In one example these coupling struts 233 can be generally straight struts running parallel to the central longitudinal axis 8 of the device. In other examples the coupling struts 233 may have a plurality of struts configured in one or more cells or may have curved or spiral arms. The regions between adjacent expandable bodies 216, 217 can form inlets 214 through which the clot or portions of the clot may pass and enter the reception space 9 between the elongate inner body 110 and the outer cage 210.
The distal-most portion of the outer cage 210 can have a tapered end 218 which slims down radially in a substantially conical profile to a distal junction 213. The tapering and convergence of struts at the tapered end 218 reduces the pore size of the openings between struts to create a fragment capture zone. These struts can be end crown struts 237 connected to the distal-most distal expandable body 217 via connecting struts 234, as shown in
Distal expandable bodies 217 can in turn be connected by one or more connecting arms 234, which can extend from a proximal junction 239 to a distal junction 240, as seen in the side view of the outer cage 210 in
The proximal and distal expandable bodies 216, 217 of the outer cage 210 can have a series of interconnected struts to form the closed cells, with certain struts such as crown strut 232 terminating in crowns or distal apices 236 with no distal connecting elements to any adjacent closed cells, and other body struts such as 242 terminating in body junction points 244. The distal apices 236 can be offset from the longitudinal axis 8 of the device 100 and can be close to the cylindrical plane defined by the outer cage 210 when expanded. The crown struts 232 which join at a distal apex 236 can be broadly curved in order to maximize the offset and spacing between apices in order to achieve a desirable balance between clot scaffolding and device flexibility. Having the free apices 236 with no distal connections at some junctions can provide greater bending flexibility for the device. This is because, in addition to the flexing of the struts forming each cell, the apices themselves can flex to accommodate bends in the vasculature and have some capacity to react to clot forces.
The outer cage 210 can expand and contact the vessel wall as the microcatheter is retracted during device deployment. The contact provides stability to the device 100 and minimizes twisting as the inner elongate body 110 and any spiral portions of the pinching section 120 is unsheathed in the vessel. This facilitates uniform deployment and expansion of the device 100 in the obstruction or clot.
Expansion of the outer cage 210 can cause compression and/or displacement of the clot during the expansion, depending on the level of scaffolding support provided by the struts. When an expandable body provides a high level of scaffolding, the clot can be compressed. Alternately, when an expandable body provides an escape path or opening the expanding body will urge the clot towards the opening. The clot itself can have many degrees of freedom and can move in a variety of different directions. By providing an outer cage 210 whose length is substantially as long as the length of the occlusive clot or longer, many of the degrees of movement freedom available to the clot are removed. Inlet openings 214 are provided in the outer cage 210 to guide the primary movement freedom available to the clot and so the expansion of the outer cage urges the clot into the reception space 9. This allows the clot to be retrieved without being excessively compressed. This is advantageous because compression of the clot can cause it to dehydrate, which in turn increases the frictional properties and stiffness, which makes the clot more difficult to disengage and remove from the vessel. This compression can be avoided if the clot easily migrates inward through the cells or the gaps in the proximal portion of the outer cage as the outer cage expands outward towards the vessel wall.
Another advantage of using self-expanding bodies is that because of the volumetric properties and stiffness of a target clot, resistance can cause the device 100 to initially expand to only a fraction of its freely expanded diameter when deployed across the clot. This gives the outer cage 210 the capacity to further expand to a larger diameter while being retracted so that it can remain in contact with vessel walls as it is retracted into progressively larger and more proximal vessels.
The elongate inner body 110 can be configured to expand to a lesser diameter than that of the smallest vessel in which it is intended to be used. When the inner body is non-tapered, this diameter is typically less than 50% that of the expanded outer cage diameter and in some cases may be as low as 20% or less of the outer cage diameter. This allows portions of the inner body can be constructed with a very small volume of material, as it is only required to expand to a fraction of the diameter of the outer cage and can thus be highly flexible in both the collapsed and expanded states. This flexibility can advantageously allow the inner body to be displaced in one direction by one portion of the clot and another direction by another portion of the clot.
The clot pinching section 120 can be an engaging element in the more proximal region of the inner elongate body 110 of the device 100. The pinching section 120 is intended to facilitate clot retrieval by expanding between the clot and the vessel wall in such a way as to engage with a clot over a significant surface area and do so with minimal compression of the clot. The overall clot compression is minimized because the section can be constructed to have rings of high compression with deep strut embedding interspersed with areas of minimal clot compression and low radial force. A portion of a clot can protrude into the area of low compression and be pinched between the tip of a catheter and the struts of the device. The pinch is achieved by forwarding a microcatheter or outer catheter over the proximal end 121 of the pinching section 120 until a portion of clot is compressed between the tip of the catheter and a crown or strut of the pinching section. This pinch facilitates removal of the clot as it increases the grip of the device on the clot, particularly for fibrin rich clots. It may also elongate the clot, thereby reducing the dislodgement force by pulling the clot away from the vessel wall during the dislodgement process. Retention of the clot during can be improved during retraction to the microcatheter or outer catheter by controlling the proximal end of the clot and preventing it from snagging on a side branch vessel.
Distal of the clot pinching section 120, the inner channel 130 can be generally tubular, planar, or some other shape, with a luminal structure being smaller in diameter than the surrounding portions of the outer cage 210. In one example, the distal inner channel 130 can transition from the distal end 122 of the clot pinching section to form a barrel shape so that this section is a smaller or larger radial size than that of the proximal pinch section 120 in the illustrated expanded configuration. This allows a flow channel to be created across very long clots without overly compressing the clot or engaging the inner channel 130 with the vessel wall. The inner channel 130 can be formed monolithically with the pinching section or can be formed separately and connected through a collar or other mechanical joint. In other cases, the inner channel 130 may have a non-cylindrical cross-section, may be non-uniform in diameter, and may have tailored strut patterns to provide regions of differing radial force or flexibility.
In another example, the shape can be substantially tubular and have a plurality of struts converging away from and towards the axis 8 of the device in intervals as shown in
The distal end 136 of the inner channel 130 can transition to or be connected with a tether or shaft to a fragment protection structure 14. The fragment protection structure 14 can be a plurality of struts configured in a volumetric pattern, in a weave or entangled mesh filter, or in a basket-like or conical shape to impede or collect fragments from travelling distal of the device. The structure 14 can also be a bundle of fibers in a spherical or similar shape, and in the expanded state at least a portion of the fragment protection structure has a radial size larger than the flow channel 130 and pinching section 120 and can be similar in size to the diameter of the target blood vessel. The distal end of the fragment protection element 14 can have a radiopaque coil element 16, which can be laser cut from the same tubing used in the construction of the inner channel 130 during processing.
The inner elongate body 110 and outer cage 210 can be joined proximally at the shaft 6 and also distally during assembly so as to minimize tension between the members during use. The struts of the clot pinching segment 120, the inner channel 130, or both, can lengthen and shorten so that the lengths of the inner body and outer cage are substantially the same when loaded in a microcatheter and when freely expanded at the target site. The closed cells of the inner body and outer cage, along the coil element 16, can allow the device to accommodate minor length differentials through stretching without the application of significant tensile or compressive forces to the joints. Length differentials can occur when, for example, the device is expanded, collapsed, or deployed in a small vessel.
An enlarged and magnified view of the clot pinching section 120 of the inner elongate body 110 of
The longitudinal length of the bridge struts in the low density fluting 146 between the ring segments 145 can vary. When used in the middle cerebral artery, for example, the longitudinal spacing can be approximately 3-6 mm. This spacing allows the clot to protrude between the struts where it engages the pinching section in the expanded deployed configuration. The total length and/or number of ring segments 145 and fluting sections 146 can be optimized for the expected length and density for optimum embedding in the clot. The bridge struts 144 between the ring segments 145 can be straight and parallel with the axis 8 of the device for better pushability to ensure the device can be delivered through tortuous anatomy.
Struts in the pinching section 120 can also have one or more bends 148 at various axial positions along their length. The “dog-leg” type shape created by these bends 148 in the struts 144 can be repeated around the circumference or radial direction of the section to form cells. The angle formed by the bends 148 or the length of the struts 144 can be varied in places, or different struts in the pattern can also have different widths so that various segments can have higher expansion force for improved engagement with the clot in the expanded deployed configuration. This structure can be produced by laser cutting Nitinol stock and heat-setting the shape so that it assumes the desired profile when expanded.
Another example of an inner elongate body 110 which has a proximal engaging element configured as a clot engaging pinching section 120 and a distal inner channel 130 is illustrated in
The pinching section 120 can have more densely spaced ring segments 145 along portions of its length as compared to that in
During retraction, the pinch of a fibrin rich clot may be lost, or the clot may contain red blood cell rich ‘soft’ segments which are not fully gripped on the proximal pinch section 120. In these scenarios, the struts of the distal porous inner channel 130 can provide engagement with the clot and retrieve it through the increased diameter vessels, past the bends and branches to the microcatheter or outer catheter. Further, the expanded cells and/or struts of the fragment protection element 14 engage with any liberated fragments or ungripped clot sections with minimal shear.
Referring to
The inner body 110 can have a proximal clot engaging element 120 and a more distal tubular inner channel 130. A three-dimensional mesh-like structure or basket can be formed from wire or fiber into a fragment protection element 14, which is retained at the distal end 136 of the distal inner channel 130 and within the outer cage 210. The wire or fibers may be randomly curled and/or twisted to occupy the space within the structure, or they may be shaped into a specific pattern.
The clot engaging element 120 can have struts forming a plurality of adjacent segments 152, where differing shapes of the adjacent segments results in the radial force generated by successive adjacent segments being unequal. Some struts can have bends 148 (such as those seen in
In another example of the device 100 shown in
When deployed across a clot, portions of the clot can migrate through the inlets 214 and cells of the expandable bodies 216, 217 of the outer cage 210, or the spaces between expandable bodies, and into the reception space 9 or the device. Here, the clot can protrude into areas of low strut density and also into the central lumen of the helical spiral pattern of the clot pinching structure 120. The gaps and lower scaffolding of the proximal expandable bodies 216 facilitate ingress to the spiral of the clot pinching structure 120. When the device 100 is subsequently retracted, this spiral can improve grip and dislodgement performance and facilitate the clot pinching action when an outer catheter is forwarded distally to transition the device from the expanded deployed configuration to the partially constrained clot pinching configuration. Such an effect can also be increased if the clot pinching structure 120 of the device 100 was constructed from two or more helical spiral components.
A helical spiral shape can also allow portions of the clot pinching structure 120 to elongate under tension, stretching parts of the clot during dislodgement. The proximal end of the clot can be pinched and constrained on the clot pinching structure 120 while the distal end of the clot can be positioned on the inner channel 130 to embed and open a flow channel. If the distal end of the clot remains stuck in the vessel, the inner channel 130 and outer cage 210 can remain static while the clot pinching section 120 expands in some sections and contracts in others in response to clot forces. This action can help peel the clot from the vessel wall and reduce the dislodgement force during the procedure.
A fragment protection element 14 can be connected by a tether or shaft 134 to the distal end 136 of the inner channel 130. The protection element 14 can be a volumetric pattern which expands to a larger radial size than the radial size at any point along the cross section of the elongate inner body 110. The shape of the element can be a conical basket as shown or a mesh element or fibrous bundle occupying sufficient space to impede the distal passage of clot or thrombus fragments.
The exact shape and configuration of the strut network and adjacent segments 152 of the clot pinching element 120 will determine the radial force extorted at different axial positions along the structure when the element is in the expanded deployed configuration and clot pinching configuration. The force can vary, for example, in a generally sinusoidal waveform pattern 124 with locally varying peaks 126 determining the amplitude 128 of force at that position. A sample plot of radial force as a function of axial position along the clot engaging element 120 is shown to illustrate this concept in
As a microcatheter or outer catheter is advanced to increase the pinch on a clot, the user may feel the pinching as resistance and stop advancement of the catheter, or alternately may advance a fixed distance over the proximal end 121 of the engaging element 120 and the more proximal expandable bodies 216 of the outer cage 210. The lower level of scaffolding in the proximal expandable bodies 216 of the outer cage 210 allows the relative tension between the engaging element 120 and catheter to be maintained so that the pinch between the engaging element and the catheter does not deteriorate during retraction of the clot.
The relative tension between the device and the microcatheter can be maintained by the user during dislodgment and retraction to ensure the pinch on the clot is maintained, as in
Referring to a method 1200 outlined in
Step 1220 can provide for a clot retrieval device having a collapsed delivery configuration, an expanded deployed configuration, and an expandable element. A proximal shaft can be used to manipulate the device during a procedure. The expandable element can have an inner body and an outer body expandable to a greater radial extent than the inner body. The inner body can have a proximal pinching element and a distal flow channel element. The outer body can have a non-circumferential first scaffolding section disposed around the pinching element and a fully circumferential second scaffolding section around the flow channel element and connected distal of the first scaffolding section. The non-circumferential first scaffolding segment can allow for portions of the clot in the vicinity can easily pass inward through gaps in the outer body to engage with the proximal pinching element of the inner body.
Step 1230 can involve delivering the clot retrieval device in the collapsed delivery configuration to the occluded vessel through a microcatheter. In the case of an intracranial occlusion a variety of access routes are possible, including a direct stick into the carotid artery, a brachial approach, or a femoral access. Once access has been gained to the arterial system using conventional and well understood techniques, a guide catheter or long sheath (not shown as part of
The microcatheter can then be retracted allowing the clot retrieval device to expand within and either side of the clot in step 1240. This step can further involve the scaffolding regions of the outer body expanding within the clot to apply a compressive force to urge the clot to flow through the inlet cells and into the space between the inner and outer bodies. As the outer body is deployed to the expanded deployed configuration, at least a portion of the clot can pass radially through circumferential gaps in the non-circumferential first scaffolding section and into contact with at least a portion of the pinching element. Because of the large cell openings in the outer body, and the gaps in the non-circumferential first scaffolding section, clot compression can be controlled and minimized. Minimizing compression on the clot reduces the forces applied radially outward to the vessel wall, which in turn reduces the frictional forces to be overcome when retracting the clot.
Continuing to
While rigidly maintaining the position of the clot retrieval device, step 1320 can involve advancing the outer catheter along the elongate shaft so that the collar of the outer catheter engages with the expandable element to pinch in compression at least a portion of the clot with the pinching element. This can be done with the aid of aspiration through the outer and/or guide catheter to assist in retaining a firm grip on the clot and avoiding fragment loss. However, the disclosed designs grip the clot securely and houses the clot safely within a reception space, with the added benefit of having a distal fragment protection element and scaffolding region. The protection element may be spaced apart from the distal end of the inner member, so it is optimally positioned to trap any fragments released from the clot during retraction.
In step 1330, the outer catheter and the clot retrieval device are withdrawn in unison from the vessel while maintaining the engagement between the collar of the outer catheter and the expandable element. Along with aspiration, this engagement maintains the firm pinching grip on the clot as it is withdrawn through bends and successively larger vessel diameters.
In step 1340, the clot retrieval device and the pinched clot can be removed from the patient. The device may be rinsed in saline and gently cleaned before being reloaded into the microcatheter, if required. It can then be reintroduced into the vasculature to be redeployed in additional segments of an occlusive clot, or if further passes for complete recanalization are needed.
The invention is not necessarily limited to the examples described, which can be varied in construction and detail. The terms “distal” and “proximal” are used throughout the preceding description and are meant to refer to a positions and directions relative to a treating physician. As such, “distal” or distally” refer to a position distant to or a direction away from the physician. Similarly, “proximal” or “proximally” refer to a position near to or a direction towards the physician. Furthermore, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
As used herein, the terms “about” or “approximately” for any numerical values or ranges indicate a suitable dimensional tolerance that allows the part or collection of components to function for its intended purpose as described herein. More specifically, “about” or “approximately” may refer to the range of values ±20% of the recited value, e.g. “about 90%” may refer to the range of values from 71% to 99%.
In describing example embodiments, terminology has been resorted to for the sake of clarity. It is intended that each term contemplates its broadest meaning as understood by those skilled in the art and includes all technical equivalents that operate in a similar manner to accomplish a similar purpose without departing from the scope and spirit of the invention. It is also to be understood that the mention of one or more steps of a method does not preclude the presence of additional method steps or intervening method steps between those steps expressly identified. Similarly, some steps of a method can be performed in a different order than those described herein without departing from the scope of the disclosed technology. For clarity and conciseness, not all possible combinations have been listed, and such variants are often apparent to those of skill in the art and are intended to be within the scope of the claims which follow.
The present application is a divisional application of U.S. patent application Ser. No. 16/946,362 filed Jun. 18, 2020. The entire contents of which are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
4455717 | Gray | Jun 1984 | A |
4611594 | Grayhack et al. | Sep 1986 | A |
4612931 | Dormia | Sep 1986 | A |
4643184 | Mobin-Uddin | Feb 1987 | A |
4727873 | Mobin-Uddin | Mar 1988 | A |
4793348 | Palmaz | Dec 1988 | A |
4873978 | Ginsburg | Oct 1989 | A |
5011488 | Ginsburg | Apr 1991 | A |
5084065 | MacGregor et al. | Jan 1992 | A |
5092839 | Kipperman | Mar 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5102415 | Guenther et al. | Apr 1992 | A |
5108419 | Reger et al. | Apr 1992 | A |
5122136 | Guglielmi et al. | Jun 1992 | A |
5163951 | Pinchuk et al. | Nov 1992 | A |
5171233 | Amplatz et al. | Dec 1992 | A |
5171259 | Inoue | Dec 1992 | A |
5217441 | Shichman | Jun 1993 | A |
5234437 | Sepetka | Aug 1993 | A |
5236447 | Kubo et al. | Aug 1993 | A |
5330482 | Gibbs et al. | Jul 1994 | A |
5383887 | Nadal | Jan 1995 | A |
5387219 | Rappe | Feb 1995 | A |
5387226 | Miraki | Feb 1995 | A |
5449372 | Schmaltz et al. | Sep 1995 | A |
5499985 | Hein et al. | Mar 1996 | A |
5538512 | Zenzon et al. | Jul 1996 | A |
5538515 | Kafry et al. | Jul 1996 | A |
5549626 | Miller et al. | Aug 1996 | A |
5558652 | Henke | Sep 1996 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5639277 | Mariant et al. | Jun 1997 | A |
5639278 | Dereume et al. | Jun 1997 | A |
5645558 | Horton | Jul 1997 | A |
5653605 | Woehl et al. | Aug 1997 | A |
5658296 | Bates et al. | Aug 1997 | A |
5665117 | Rhodes | Sep 1997 | A |
5695519 | Summers et al. | Dec 1997 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713853 | Clark et al. | Feb 1998 | A |
5733325 | Robinson et al. | Mar 1998 | A |
5769871 | Mers Kelly et al. | Jun 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5779686 | Sato et al. | Jul 1998 | A |
5779716 | Cano et al. | Jul 1998 | A |
5800519 | Sandock | Sep 1998 | A |
5810874 | Lefebvre | Sep 1998 | A |
5814064 | Daniel et al. | Sep 1998 | A |
5824041 | Lenker et al. | Oct 1998 | A |
5827304 | Hart | Oct 1998 | A |
5853422 | Huebsch et al. | Dec 1998 | A |
5855598 | Pinchuk | Jan 1999 | A |
5893869 | Barnhart et al. | Apr 1999 | A |
5895398 | Wensel et al. | Apr 1999 | A |
5897567 | Ressemann et al. | Apr 1999 | A |
5904698 | Thomas et al. | May 1999 | A |
5911702 | Romley et al. | Jun 1999 | A |
5911725 | Boury | Jun 1999 | A |
5919126 | Armini | Jul 1999 | A |
5931509 | Bartholomew | Aug 1999 | A |
5935139 | Bates | Aug 1999 | A |
5947995 | Samuels | Sep 1999 | A |
6063113 | Kavteladze et al. | May 2000 | A |
6066149 | Samson et al. | May 2000 | A |
6066158 | Engelson et al. | May 2000 | A |
6093196 | Okada | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6096053 | Bates | Aug 2000 | A |
6099534 | Bates et al. | Aug 2000 | A |
6099559 | Nolting | Aug 2000 | A |
6102932 | Kurz | Aug 2000 | A |
6106548 | Roubin et al. | Aug 2000 | A |
6129739 | Khosravi | Oct 2000 | A |
6143022 | Shull et al. | Nov 2000 | A |
6146404 | Kim et al. | Nov 2000 | A |
6156064 | Chouinard | Dec 2000 | A |
6165194 | Denardo | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6168604 | Cano | Jan 2001 | B1 |
6168622 | Mazzocchi | Jan 2001 | B1 |
6174318 | Bates et al. | Jan 2001 | B1 |
6174329 | Callol et al. | Jan 2001 | B1 |
6179861 | Khosravi et al. | Jan 2001 | B1 |
6203561 | Ramee et al. | Mar 2001 | B1 |
6214026 | Lepak et al. | Apr 2001 | B1 |
6221006 | Dubrul et al. | Apr 2001 | B1 |
6221096 | Aiba et al. | Apr 2001 | B1 |
6231597 | Deem et al. | May 2001 | B1 |
6238412 | Dubrul et al. | May 2001 | B1 |
6245012 | Kleshinski | Jun 2001 | B1 |
6245087 | Addis | Jun 2001 | B1 |
6251122 | Tsukernik | Jun 2001 | B1 |
6254571 | Hart | Jul 2001 | B1 |
6264663 | Cano | Jul 2001 | B1 |
6267777 | Bosma et al. | Jul 2001 | B1 |
6290710 | Cryer et al. | Sep 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6315778 | Gambale et al. | Nov 2001 | B1 |
6325815 | Kusleika et al. | Dec 2001 | B1 |
6325819 | Pavcnik et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6336934 | Gilson et al. | Jan 2002 | B1 |
6346116 | Brooks et al. | Feb 2002 | B1 |
6348056 | Bates et al. | Feb 2002 | B1 |
6350271 | Kurz et al. | Feb 2002 | B1 |
6355057 | DeMarais et al. | Mar 2002 | B1 |
6361545 | Macoviak et al. | Mar 2002 | B1 |
6364895 | Greenhalgh | Apr 2002 | B1 |
6375668 | Gifford et al. | Apr 2002 | B1 |
6375670 | Greenhalgh | Apr 2002 | B1 |
6383205 | Samson et al. | May 2002 | B1 |
6383206 | Gillick et al. | May 2002 | B1 |
6391037 | Greenhalgh | May 2002 | B1 |
6402771 | Palmer et al. | Jun 2002 | B1 |
6416541 | Denardo | Jul 2002 | B2 |
6425909 | Dieck et al. | Jul 2002 | B1 |
6428558 | Jones et al. | Aug 2002 | B1 |
6432122 | Gilson et al. | Aug 2002 | B1 |
6436112 | Wensel et al. | Aug 2002 | B2 |
6458139 | Palmer et al. | Oct 2002 | B1 |
6485497 | Wensel et al. | Nov 2002 | B2 |
6485501 | Green | Nov 2002 | B1 |
6485502 | Don Michael et al. | Nov 2002 | B2 |
6488701 | Nolting et al. | Dec 2002 | B1 |
6511492 | Rosenbluth et al. | Jan 2003 | B1 |
6530935 | Wensel et al. | Mar 2003 | B2 |
6530939 | Hopkins et al. | Mar 2003 | B1 |
6537294 | Boyle et al. | Mar 2003 | B1 |
6540768 | Diaz et al. | Apr 2003 | B1 |
6544279 | Hopkins et al. | Apr 2003 | B1 |
6551341 | Boylan et al. | Apr 2003 | B2 |
6551342 | Shen et al. | Apr 2003 | B1 |
6575996 | Denison et al. | Jun 2003 | B1 |
6575997 | Palmer et al. | Jun 2003 | B1 |
6582448 | Boyle et al. | Jun 2003 | B1 |
6585756 | Strecker | Jul 2003 | B1 |
6589265 | Palmer et al. | Jul 2003 | B1 |
6592607 | Palmer et al. | Jul 2003 | B1 |
6592614 | Lenker et al. | Jul 2003 | B2 |
6592616 | Stack et al. | Jul 2003 | B1 |
6602265 | Dubrul et al. | Aug 2003 | B2 |
6602271 | Adams et al. | Aug 2003 | B2 |
6602272 | Boylan et al. | Aug 2003 | B2 |
6605102 | Mazzocchi et al. | Aug 2003 | B1 |
6610077 | Hancock et al. | Aug 2003 | B1 |
6616679 | Khosravi et al. | Sep 2003 | B1 |
6632241 | Hancock et al. | Oct 2003 | B1 |
6638245 | Miller et al. | Oct 2003 | B2 |
6638293 | Makower et al. | Oct 2003 | B1 |
6641590 | Palmer et al. | Nov 2003 | B1 |
6656218 | Denardo et al. | Dec 2003 | B1 |
6660021 | Palmer et al. | Dec 2003 | B1 |
6663650 | Sepetka et al. | Dec 2003 | B2 |
6673089 | Yassour et al. | Jan 2004 | B1 |
6685722 | Rosenbluth et al. | Feb 2004 | B1 |
6692504 | Kurz et al. | Feb 2004 | B2 |
6692508 | Wensel et al. | Feb 2004 | B2 |
6692509 | Wensel et al. | Feb 2004 | B2 |
6695858 | Dubrul et al. | Feb 2004 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6702834 | Boylan et al. | Mar 2004 | B1 |
6709465 | Mitchell et al. | Mar 2004 | B2 |
6712834 | Yassour et al. | Mar 2004 | B2 |
6726701 | Gilson et al. | Apr 2004 | B2 |
6726703 | Broome et al. | Apr 2004 | B2 |
6730104 | Sepetka et al. | May 2004 | B1 |
6783528 | Vincent-Prestigiacomo | Aug 2004 | B2 |
6783538 | McGuckin, Jr. et al. | Aug 2004 | B2 |
6824545 | Sepetka et al. | Nov 2004 | B2 |
6855155 | Denardo et al. | Feb 2005 | B2 |
6878163 | Denardo et al. | Apr 2005 | B2 |
6890340 | Duane | May 2005 | B2 |
6913612 | Palmer et al. | Jul 2005 | B2 |
6913618 | Denardo et al. | Jul 2005 | B2 |
6939361 | Kleshinski | Sep 2005 | B1 |
6953472 | Palmer et al. | Oct 2005 | B2 |
6989019 | Mazzocchi et al. | Jan 2006 | B2 |
6989021 | Bosma et al. | Jan 2006 | B2 |
6994718 | Groothuis et al. | Feb 2006 | B2 |
7004954 | Voss et al. | Feb 2006 | B1 |
7004955 | Shen et al. | Feb 2006 | B2 |
7004956 | Palmer et al. | Feb 2006 | B2 |
7008434 | Kurz et al. | Mar 2006 | B2 |
7033376 | Tsukernik | Apr 2006 | B2 |
7041116 | Goto et al. | May 2006 | B2 |
7048758 | Boyle et al. | May 2006 | B2 |
7052500 | Bashiri et al. | May 2006 | B2 |
7058456 | Pierce | Jun 2006 | B2 |
7063707 | Bose et al. | Jun 2006 | B2 |
7083633 | Morrill et al. | Aug 2006 | B2 |
7083822 | Brightbill | Aug 2006 | B2 |
7094249 | Broome et al. | Aug 2006 | B1 |
7097653 | Freudenthal et al. | Aug 2006 | B2 |
7101380 | Khachin et al. | Sep 2006 | B2 |
7172614 | Boyle et al. | Feb 2007 | B2 |
7175655 | Molaei | Feb 2007 | B1 |
7179273 | Palmer et al. | Feb 2007 | B1 |
7185922 | Takayanagi et al. | Mar 2007 | B2 |
7220271 | Clubb et al. | May 2007 | B2 |
7226464 | Garner et al. | Jun 2007 | B2 |
7229472 | DePalma et al. | Jun 2007 | B2 |
7241304 | Boyle et al. | Jul 2007 | B2 |
7241308 | Andreas et al. | Jul 2007 | B2 |
7288112 | Denardo et al. | Oct 2007 | B2 |
7300458 | Henkes et al. | Nov 2007 | B2 |
7306618 | Demond et al. | Dec 2007 | B2 |
7314483 | Landau et al. | Jan 2008 | B2 |
7316692 | Huffmaster | Jan 2008 | B2 |
7323001 | Clubb et al. | Jan 2008 | B2 |
7331976 | McGuckin, Jr. et al. | Feb 2008 | B2 |
7344550 | Carrison et al. | Mar 2008 | B2 |
7399308 | Borillo et al. | Jul 2008 | B2 |
7410491 | Hopkins et al. | Aug 2008 | B2 |
7425215 | Boyle et al. | Sep 2008 | B2 |
7452496 | Brady et al. | Nov 2008 | B2 |
7491215 | Vale et al. | Feb 2009 | B2 |
7491216 | Brady | Feb 2009 | B2 |
7510565 | Gilson et al. | Mar 2009 | B2 |
7534252 | Sepetka et al. | May 2009 | B2 |
7556636 | Mazzocchi et al. | Jul 2009 | B2 |
7582111 | Krolik et al. | Sep 2009 | B2 |
7594926 | Linder et al. | Sep 2009 | B2 |
7604649 | McGuckin, Jr. et al. | Oct 2009 | B2 |
7604650 | Bergheim | Oct 2009 | B2 |
7618434 | Santra et al. | Nov 2009 | B2 |
7662165 | Gilson et al. | Feb 2010 | B2 |
7670356 | Mazzocchi et al. | Mar 2010 | B2 |
7678123 | Chanduszko | Mar 2010 | B2 |
7691121 | Rosenbluth et al. | Apr 2010 | B2 |
7691124 | Balgobin | Apr 2010 | B2 |
7708770 | Linder et al. | May 2010 | B2 |
7717929 | Fallman | May 2010 | B2 |
7736385 | Agnew | Jun 2010 | B2 |
7749246 | McGuckin, Jr. et al. | Jul 2010 | B2 |
7758606 | Streeter et al. | Jul 2010 | B2 |
7758611 | Kato | Jul 2010 | B2 |
7766934 | Pal et al. | Aug 2010 | B2 |
7771452 | Pal et al. | Aug 2010 | B2 |
7780694 | Palmer et al. | Aug 2010 | B2 |
7780700 | Frazier et al. | Aug 2010 | B2 |
7811305 | Balgobin et al. | Oct 2010 | B2 |
7815659 | Conlon et al. | Oct 2010 | B2 |
7819893 | Brady et al. | Oct 2010 | B2 |
7828815 | Mazzocchi et al. | Nov 2010 | B2 |
7828816 | Mazzocchi et al. | Nov 2010 | B2 |
7833240 | Okushi et al. | Nov 2010 | B2 |
7842053 | Chanduszko et al. | Nov 2010 | B2 |
7846175 | Bonnette et al. | Dec 2010 | B2 |
7846176 | Gilson et al. | Dec 2010 | B2 |
7850708 | Pal | Dec 2010 | B2 |
7883516 | Huang et al. | Feb 2011 | B2 |
7887560 | Kusleika | Feb 2011 | B2 |
7901426 | Gilson et al. | Mar 2011 | B2 |
7914549 | Morsi | Mar 2011 | B2 |
7922732 | Mazzocchi et al. | Apr 2011 | B2 |
7927784 | Simpson | Apr 2011 | B2 |
7931659 | Bose et al. | Apr 2011 | B2 |
7998165 | Huffmaster | Aug 2011 | B2 |
8002822 | Glocker et al. | Aug 2011 | B2 |
8021379 | Thompson et al. | Sep 2011 | B2 |
8021380 | Thompson et al. | Sep 2011 | B2 |
8043326 | Hancock et al. | Oct 2011 | B2 |
8048151 | OBrien et al. | Nov 2011 | B2 |
8052640 | Fiorella et al. | Nov 2011 | B2 |
8057497 | Raju et al. | Nov 2011 | B1 |
8057507 | Horan et al. | Nov 2011 | B2 |
8066757 | Ferrera et al. | Nov 2011 | B2 |
8070791 | Ferrera et al. | Dec 2011 | B2 |
8088140 | Ferrera et al. | Jan 2012 | B2 |
8100935 | Rosenbluth et al. | Jan 2012 | B2 |
8109941 | Richardson | Feb 2012 | B2 |
8118829 | Carrison et al. | Feb 2012 | B2 |
8118856 | Schreck et al. | Feb 2012 | B2 |
8123769 | Osborne | Feb 2012 | B2 |
8137376 | Clubb et al. | Mar 2012 | B2 |
8137377 | Palmer et al. | Mar 2012 | B2 |
8142422 | Makower et al. | Mar 2012 | B2 |
8142442 | Palmer et al. | Mar 2012 | B2 |
8182508 | Magnuson et al. | May 2012 | B2 |
8187298 | Pal | May 2012 | B2 |
8246641 | Osborne et al. | Aug 2012 | B2 |
8246672 | Osborne | Aug 2012 | B2 |
8252017 | Paul, Jr. et al. | Aug 2012 | B2 |
8252018 | Valaie | Aug 2012 | B2 |
8262689 | Schneiderman et al. | Sep 2012 | B2 |
8282668 | McGuckin, Jr. et al. | Oct 2012 | B2 |
8298257 | Sepetka et al. | Oct 2012 | B2 |
RE43882 | Hopkins et al. | Dec 2012 | E |
8357178 | Grandfield et al. | Jan 2013 | B2 |
8357179 | Grandfield et al. | Jan 2013 | B2 |
8357180 | Feller, III et al. | Jan 2013 | B2 |
8357893 | Xu et al. | Jan 2013 | B2 |
8361095 | Osborne | Jan 2013 | B2 |
8361110 | Chanduszko | Jan 2013 | B2 |
8366663 | Fiorella et al. | Feb 2013 | B2 |
8409215 | Sepetka et al. | Apr 2013 | B2 |
8414482 | Belson | Apr 2013 | B2 |
8414543 | McGuckin, Jr. et al. | Apr 2013 | B2 |
8419748 | Valaie | Apr 2013 | B2 |
8460312 | Bose et al. | Jun 2013 | B2 |
8460313 | Huffmaster | Jun 2013 | B2 |
8486104 | Samson et al. | Jul 2013 | B2 |
8512352 | Martin | Aug 2013 | B2 |
8529596 | Grandfield et al. | Sep 2013 | B2 |
8545526 | Martin et al. | Oct 2013 | B2 |
8574262 | Ferrera et al. | Nov 2013 | B2 |
8579915 | French et al. | Nov 2013 | B2 |
8585713 | Ferrera et al. | Nov 2013 | B2 |
8608761 | Osborne et al. | Dec 2013 | B2 |
8679142 | Slee et al. | Mar 2014 | B2 |
8690907 | Janardhan et al. | Apr 2014 | B1 |
8696622 | Fiorella et al. | Apr 2014 | B2 |
8702652 | Fiorella et al. | Apr 2014 | B2 |
8702704 | Shelton, IV et al. | Apr 2014 | B2 |
8702724 | Olsen et al. | Apr 2014 | B2 |
8777976 | Brady et al. | Jul 2014 | B2 |
8777979 | Shrivastava et al. | Jul 2014 | B2 |
8784434 | Rosenbluth et al. | Jul 2014 | B2 |
8784441 | Rosenbluth et al. | Jul 2014 | B2 |
8795305 | Martin et al. | Aug 2014 | B2 |
8795317 | Grandfield et al. | Aug 2014 | B2 |
8795345 | Grandfield et al. | Aug 2014 | B2 |
8814892 | Galdonik et al. | Aug 2014 | B2 |
8814925 | Hilaire et al. | Aug 2014 | B2 |
8852205 | Brady et al. | Oct 2014 | B2 |
8870941 | Evans et al. | Oct 2014 | B2 |
8900265 | Ulm, III | Dec 2014 | B1 |
8920358 | Levine et al. | Dec 2014 | B2 |
8939991 | Krolik et al. | Jan 2015 | B2 |
8945143 | Ferrera et al. | Feb 2015 | B2 |
8945160 | Krolik et al. | Feb 2015 | B2 |
8945169 | Pal | Feb 2015 | B2 |
8945172 | Ferrera et al. | Feb 2015 | B2 |
8956399 | Cam et al. | Feb 2015 | B2 |
8968330 | Rosenbluth et al. | Mar 2015 | B2 |
9011481 | Aggerholm et al. | Apr 2015 | B2 |
9039749 | Shrivastava et al. | May 2015 | B2 |
9072537 | Grandfield et al. | Jul 2015 | B2 |
9095342 | Becking et al. | Aug 2015 | B2 |
9113936 | Palmer et al. | Aug 2015 | B2 |
9119656 | Bose et al. | Sep 2015 | B2 |
9138307 | Valaie | Sep 2015 | B2 |
9155552 | Ulm, III | Oct 2015 | B2 |
9161758 | Figulla et al. | Oct 2015 | B2 |
9161766 | Slee et al. | Oct 2015 | B2 |
9173668 | Ulm, III | Nov 2015 | B2 |
9186487 | Dubrul et al. | Nov 2015 | B2 |
9198687 | Fulkerson et al. | Dec 2015 | B2 |
9204887 | Cully et al. | Dec 2015 | B2 |
9211132 | Bowman | Dec 2015 | B2 |
9232992 | Heidner et al. | Jan 2016 | B2 |
9254371 | Martin et al. | Feb 2016 | B2 |
9301769 | Brady et al. | Apr 2016 | B2 |
9332999 | Ray et al. | May 2016 | B2 |
9402707 | Brady et al. | Aug 2016 | B2 |
9445829 | Brady et al. | Sep 2016 | B2 |
9456834 | Folk | Oct 2016 | B2 |
9532792 | Galdonik et al. | Jan 2017 | B2 |
9532873 | Kelley | Jan 2017 | B2 |
9533344 | Monetti et al. | Jan 2017 | B2 |
9539011 | Chen et al. | Jan 2017 | B2 |
9539022 | Bowman | Jan 2017 | B2 |
9539122 | Burke et al. | Jan 2017 | B2 |
9539382 | Nelson | Jan 2017 | B2 |
9549830 | Bruszewski et al. | Jan 2017 | B2 |
9554805 | Tompkins et al. | Jan 2017 | B2 |
9561125 | Bowman et al. | Feb 2017 | B2 |
9572982 | Burnes et al. | Feb 2017 | B2 |
9579104 | Beckham et al. | Feb 2017 | B2 |
9579484 | Bamnell | Feb 2017 | B2 |
9585642 | Dinsmoor et al. | Mar 2017 | B2 |
9615832 | Bose et al. | Apr 2017 | B2 |
9615951 | Bennett et al. | Apr 2017 | B2 |
9622753 | Cox | Apr 2017 | B2 |
9636115 | Henry et al. | May 2017 | B2 |
9636439 | Chu et al. | May 2017 | B2 |
9642639 | Brady et al. | May 2017 | B2 |
9642675 | Werneth et al. | May 2017 | B2 |
9655633 | Leynov et al. | May 2017 | B2 |
9655645 | Staunton | May 2017 | B2 |
9655989 | Cruise et al. | May 2017 | B2 |
9662129 | Galdonik et al. | May 2017 | B2 |
9662238 | Dwork et al. | May 2017 | B2 |
9662425 | Lilja et al. | May 2017 | B2 |
9668898 | Wong | Jun 2017 | B2 |
9675477 | Thompson | Jun 2017 | B2 |
9675782 | Connolly | Jun 2017 | B2 |
9676022 | Ensign et al. | Jun 2017 | B2 |
9692557 | Murphy | Jun 2017 | B2 |
9693852 | Lam et al. | Jul 2017 | B2 |
9700262 | Janik et al. | Jul 2017 | B2 |
9700399 | Acosta-Acevedo | Jul 2017 | B2 |
9717421 | Griswold et al. | Aug 2017 | B2 |
9717500 | Tieu et al. | Aug 2017 | B2 |
9717502 | Teoh et al. | Aug 2017 | B2 |
9724103 | Cruise et al. | Aug 2017 | B2 |
9724526 | Strother et al. | Aug 2017 | B2 |
9750565 | Bloom et al. | Sep 2017 | B2 |
9757260 | Greenan | Sep 2017 | B2 |
9764111 | Gulachenski | Sep 2017 | B2 |
9770251 | Bowman et al. | Sep 2017 | B2 |
9770577 | Li et al. | Sep 2017 | B2 |
9775621 | Tompkins et al. | Oct 2017 | B2 |
9775706 | Peterson et al. | Oct 2017 | B2 |
9775732 | Khenansho | Oct 2017 | B2 |
9788800 | Mayoras, Jr. | Oct 2017 | B2 |
9795391 | Saatchi et al. | Oct 2017 | B2 |
9801651 | Harrah et al. | Oct 2017 | B2 |
9801980 | Karino et al. | Oct 2017 | B2 |
9808599 | Bowman et al. | Nov 2017 | B2 |
9833252 | Sepetka et al. | Dec 2017 | B2 |
9833304 | Horan et al. | Dec 2017 | B2 |
9833604 | Lam et al. | Dec 2017 | B2 |
9833625 | Waldhauser et al. | Dec 2017 | B2 |
9901434 | Hoffman | Feb 2018 | B2 |
9918720 | Marchand et al. | Mar 2018 | B2 |
10016206 | Yang | Jul 2018 | B1 |
10070878 | Ma | Sep 2018 | B2 |
10098651 | Marchand et al. | Oct 2018 | B2 |
10201360 | Vale et al. | Feb 2019 | B2 |
10231751 | Sos | Mar 2019 | B2 |
10292723 | Brady et al. | May 2019 | B2 |
10299811 | Brady et al. | May 2019 | B2 |
10363054 | Vale et al. | Jul 2019 | B2 |
10376274 | Farin et al. | Aug 2019 | B2 |
10390850 | Vale et al. | Aug 2019 | B2 |
10524811 | Marchand et al. | Jan 2020 | B2 |
10531942 | Eggers | Jan 2020 | B2 |
10617435 | Vale et al. | Apr 2020 | B2 |
10722257 | Skillrud et al. | Jul 2020 | B2 |
11439418 | O'Malley | Sep 2022 | B2 |
11517340 | Casey | Dec 2022 | B2 |
20010001315 | Bates et al. | May 2001 | A1 |
20010016755 | Addis | Aug 2001 | A1 |
20010037141 | Yee et al. | Nov 2001 | A1 |
20010041909 | Tsugita et al. | Nov 2001 | A1 |
20010044632 | Daniel et al. | Nov 2001 | A1 |
20010049554 | Ruiz et al. | Dec 2001 | A1 |
20010051810 | Dubrul et al. | Dec 2001 | A1 |
20020004667 | Adams et al. | Jan 2002 | A1 |
20020016609 | Wensel et al. | Feb 2002 | A1 |
20020022859 | Hogendijk | Feb 2002 | A1 |
20020026211 | Khosravi et al. | Feb 2002 | A1 |
20020042627 | Brady et al. | Apr 2002 | A1 |
20020049468 | Streeter et al. | Apr 2002 | A1 |
20020052620 | Barbut | May 2002 | A1 |
20020058911 | Gilson et al. | May 2002 | A1 |
20020068954 | Foster | Jun 2002 | A1 |
20020072764 | Sepetka et al. | Jun 2002 | A1 |
20020082558 | Samson et al. | Jun 2002 | A1 |
20020091407 | Zando-Azizi et al. | Jul 2002 | A1 |
20020095171 | Belef | Jul 2002 | A1 |
20020123765 | Sepetka et al. | Sep 2002 | A1 |
20020128680 | Pavlovic | Sep 2002 | A1 |
20020138094 | Borillo et al. | Sep 2002 | A1 |
20020143349 | Gifford, III et al. | Oct 2002 | A1 |
20020143362 | Macoviak et al. | Oct 2002 | A1 |
20020156455 | Barbut | Oct 2002 | A1 |
20020161393 | Demond et al. | Oct 2002 | A1 |
20020165576 | Boyle et al. | Nov 2002 | A1 |
20020173819 | Leeflang et al. | Nov 2002 | A1 |
20020183787 | Wahr et al. | Dec 2002 | A1 |
20020188276 | Evans et al. | Dec 2002 | A1 |
20020188314 | Anderson et al. | Dec 2002 | A1 |
20020193824 | Boylan et al. | Dec 2002 | A1 |
20020198588 | Armstrong et al. | Dec 2002 | A1 |
20030004536 | Boylan et al. | Jan 2003 | A1 |
20030004538 | Secrest et al. | Jan 2003 | A1 |
20030004540 | Linder et al. | Jan 2003 | A1 |
20030004542 | Wensel et al. | Jan 2003 | A1 |
20030009146 | Muni et al. | Jan 2003 | A1 |
20030009191 | Wensel et al. | Jan 2003 | A1 |
20030038447 | Cantele | Feb 2003 | A1 |
20030040772 | Hyodoh et al. | Feb 2003 | A1 |
20030050663 | Khachin et al. | Mar 2003 | A1 |
20030069520 | Skujins et al. | Apr 2003 | A1 |
20030114879 | Euteneuer et al. | Jun 2003 | A1 |
20030125798 | Martin | Jul 2003 | A1 |
20030130682 | Broome et al. | Jul 2003 | A1 |
20030144687 | Brady et al. | Jul 2003 | A1 |
20030144688 | Brady et al. | Jul 2003 | A1 |
20030153943 | Michael et al. | Aug 2003 | A1 |
20030153944 | Phung et al. | Aug 2003 | A1 |
20030163064 | Vrba et al. | Aug 2003 | A1 |
20030163158 | White | Aug 2003 | A1 |
20030171769 | Barbut | Sep 2003 | A1 |
20030171771 | Anderson et al. | Sep 2003 | A1 |
20030176884 | Berrada et al. | Sep 2003 | A1 |
20030187495 | Cully et al. | Oct 2003 | A1 |
20030195537 | Dubrul et al. | Oct 2003 | A1 |
20030195554 | Shen et al. | Oct 2003 | A1 |
20030199917 | Knudson et al. | Oct 2003 | A1 |
20030204202 | Palmer et al. | Oct 2003 | A1 |
20030208224 | Broome | Nov 2003 | A1 |
20030212430 | Bose et al. | Nov 2003 | A1 |
20030236533 | Wilson et al. | Dec 2003 | A1 |
20040044399 | Ventura | Mar 2004 | A1 |
20040064179 | Linder et al. | Apr 2004 | A1 |
20040068288 | Palmer et al. | Apr 2004 | A1 |
20040073243 | Sepetka et al. | Apr 2004 | A1 |
20040079429 | Miller et al. | Apr 2004 | A1 |
20040082962 | Demarais et al. | Apr 2004 | A1 |
20040082967 | Broome et al. | Apr 2004 | A1 |
20040088001 | Bosma et al. | May 2004 | A1 |
20040093065 | Yachia et al. | May 2004 | A1 |
20040098050 | Foerster et al. | May 2004 | A1 |
20040133231 | Maitland et al. | Jul 2004 | A1 |
20040133232 | Rosenbluth et al. | Jul 2004 | A1 |
20040138692 | Phung et al. | Jul 2004 | A1 |
20040153117 | Clubb et al. | Aug 2004 | A1 |
20040153118 | Clubb et al. | Aug 2004 | A1 |
20040199201 | Kellett et al. | Oct 2004 | A1 |
20040204749 | Gunderson | Oct 2004 | A1 |
20040215318 | Kwitkin | Oct 2004 | A1 |
20040220663 | Rivelli | Nov 2004 | A1 |
20050010245 | Wasicek | Jan 2005 | A1 |
20050033348 | Sepetka et al. | Feb 2005 | A1 |
20050038447 | Huffmaster | Feb 2005 | A1 |
20050038468 | Panetta et al. | Feb 2005 | A1 |
20050043759 | Chanduszko | Feb 2005 | A1 |
20050049619 | Sepetka et al. | Mar 2005 | A1 |
20050049669 | Jones et al. | Mar 2005 | A1 |
20050049670 | Jones et al. | Mar 2005 | A1 |
20050055033 | Leslie et al. | Mar 2005 | A1 |
20050055047 | Greenhalgh | Mar 2005 | A1 |
20050059995 | Sepetka et al. | Mar 2005 | A1 |
20050085849 | Sepetka et al. | Apr 2005 | A1 |
20050090779 | Osypka | Apr 2005 | A1 |
20050090857 | Kusleika et al. | Apr 2005 | A1 |
20050125024 | Sepetka et al. | Jun 2005 | A1 |
20050171566 | Kanamaru | Aug 2005 | A1 |
20050192627 | Whisenant et al. | Sep 2005 | A1 |
20050215942 | Abrahamson et al. | Sep 2005 | A1 |
20050216030 | Sepetka et al. | Sep 2005 | A1 |
20050216050 | Sepetka et al. | Sep 2005 | A1 |
20050228417 | Teitelbaum et al. | Oct 2005 | A1 |
20050251206 | Maahs et al. | Nov 2005 | A1 |
20050251209 | Saadat et al. | Nov 2005 | A1 |
20050267491 | Kellett et al. | Dec 2005 | A1 |
20050273135 | Chanduszko et al. | Dec 2005 | A1 |
20050283186 | Berrada et al. | Dec 2005 | A1 |
20050288686 | Sepetka et al. | Dec 2005 | A1 |
20060009798 | Callister et al. | Jan 2006 | A1 |
20060009799 | Kleshinski et al. | Jan 2006 | A1 |
20060020285 | Niermann | Jan 2006 | A1 |
20060020286 | Niermann | Jan 2006 | A1 |
20060030877 | Martinez et al. | Feb 2006 | A1 |
20060041228 | Vo et al. | Feb 2006 | A1 |
20060058836 | Bose et al. | Mar 2006 | A1 |
20060058837 | Bose et al. | Mar 2006 | A1 |
20060058838 | Bose et al. | Mar 2006 | A1 |
20060064151 | Guterman et al. | Mar 2006 | A1 |
20060069424 | Acosta et al. | Mar 2006 | A1 |
20060074477 | Berthiaume et al. | Apr 2006 | A1 |
20060142838 | Molaei et al. | Jun 2006 | A1 |
20060149313 | Arguello et al. | Jul 2006 | A1 |
20060155305 | Freudenthal et al. | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060195137 | Sepetka et al. | Aug 2006 | A1 |
20060224176 | Fung et al. | Oct 2006 | A1 |
20060224177 | Finitsis | Oct 2006 | A1 |
20060224179 | Kucharczyk et al. | Oct 2006 | A1 |
20060229638 | Abrams et al. | Oct 2006 | A1 |
20060235501 | Igaki | Oct 2006 | A1 |
20060241677 | Johnson et al. | Oct 2006 | A1 |
20060282111 | Morsi | Dec 2006 | A1 |
20060287668 | Fawzi et al. | Dec 2006 | A1 |
20060287701 | Pal | Dec 2006 | A1 |
20060293706 | Shimon | Dec 2006 | A1 |
20070010857 | Sugimoto et al. | Jan 2007 | A1 |
20070032879 | Levine et al. | Feb 2007 | A1 |
20070088382 | Bei et al. | Apr 2007 | A1 |
20070088383 | Pal et al. | Apr 2007 | A1 |
20070100348 | Cauthen, III et al. | May 2007 | A1 |
20070118173 | Magnuson et al. | May 2007 | A1 |
20070135826 | Zaver et al. | Jun 2007 | A1 |
20070149997 | Muller | Jun 2007 | A1 |
20070156170 | Hancock et al. | Jul 2007 | A1 |
20070165170 | Fukuda | Jul 2007 | A1 |
20070173921 | Wholey et al. | Jul 2007 | A1 |
20070179527 | Eskuri et al. | Aug 2007 | A1 |
20070191866 | Palmer et al. | Aug 2007 | A1 |
20070198028 | Miloslavski et al. | Aug 2007 | A1 |
20070198051 | Clubb et al. | Aug 2007 | A1 |
20070198075 | Levy | Aug 2007 | A1 |
20070208367 | Fiorella et al. | Sep 2007 | A1 |
20070208371 | French et al. | Sep 2007 | A1 |
20070225749 | Martin et al. | Sep 2007 | A1 |
20070233175 | Zaver et al. | Oct 2007 | A1 |
20070244505 | Gilson et al. | Oct 2007 | A1 |
20070270902 | Slazas et al. | Nov 2007 | A1 |
20070288054 | Tanaka et al. | Dec 2007 | A1 |
20080045881 | Teitelbaum et al. | Feb 2008 | A1 |
20080077227 | Ouellette et al. | Mar 2008 | A1 |
20080082107 | Miller et al. | Apr 2008 | A1 |
20080086190 | Ta | Apr 2008 | A1 |
20080091223 | Pokorney et al. | Apr 2008 | A1 |
20080097386 | Osypka | Apr 2008 | A1 |
20080109031 | Sepetka et al. | May 2008 | A1 |
20080109032 | Sepetka et al. | May 2008 | A1 |
20080119886 | Greenhalgh et al. | May 2008 | A1 |
20080125798 | Osborne et al. | May 2008 | A1 |
20080177296 | Sepetka et al. | Jul 2008 | A1 |
20080178890 | Townsend et al. | Jul 2008 | A1 |
20080183197 | Sepetka et al. | Jul 2008 | A1 |
20080183198 | Sepetka et al. | Jul 2008 | A1 |
20080183205 | Sepetka et al. | Jul 2008 | A1 |
20080188876 | Sepetka et al. | Aug 2008 | A1 |
20080188885 | Sepetka et al. | Aug 2008 | A1 |
20080188887 | Batiste | Aug 2008 | A1 |
20080200946 | Braun et al. | Aug 2008 | A1 |
20080200947 | Kusleika et al. | Aug 2008 | A1 |
20080215077 | Sepetka et al. | Sep 2008 | A1 |
20080221600 | Dieck et al. | Sep 2008 | A1 |
20080228209 | DeMello et al. | Sep 2008 | A1 |
20080234706 | Sepetka et al. | Sep 2008 | A1 |
20080243170 | Jenson et al. | Oct 2008 | A1 |
20080255596 | Jenson et al. | Oct 2008 | A1 |
20080262410 | Jenson et al. | Oct 2008 | A1 |
20080262528 | Martin | Oct 2008 | A1 |
20080262532 | Martin | Oct 2008 | A1 |
20080262590 | Murray | Oct 2008 | A1 |
20080269871 | Eli | Oct 2008 | A1 |
20080275488 | Fleming | Nov 2008 | A1 |
20080275493 | Farmiga | Nov 2008 | A1 |
20080281350 | Sepetka et al. | Nov 2008 | A1 |
20080296274 | Bialas et al. | Dec 2008 | A1 |
20080312681 | Ansel et al. | Dec 2008 | A1 |
20090005853 | Osman | Jan 2009 | A1 |
20090005858 | Young et al. | Jan 2009 | A1 |
20090024157 | Anukhin | Jan 2009 | A1 |
20090030443 | Buser et al. | Jan 2009 | A1 |
20090062841 | Amplatz et al. | Mar 2009 | A1 |
20090069828 | Martin et al. | Mar 2009 | A1 |
20090076539 | Valaie | Mar 2009 | A1 |
20090088793 | Bagaoisan et al. | Apr 2009 | A1 |
20090088795 | Cahill | Apr 2009 | A1 |
20090105722 | Fulkerson et al. | Apr 2009 | A1 |
20090105737 | Fulkerson et al. | Apr 2009 | A1 |
20090105747 | Chanduszko et al. | Apr 2009 | A1 |
20090149881 | Vale et al. | Jun 2009 | A1 |
20090163851 | Holloway et al. | Jun 2009 | A1 |
20090177206 | Lozier et al. | Jul 2009 | A1 |
20090182336 | Brenzel et al. | Jul 2009 | A1 |
20090281610 | Parker | Nov 2009 | A1 |
20090281619 | Le et al. | Nov 2009 | A1 |
20090287229 | Ogdahl | Nov 2009 | A1 |
20090292297 | Ferrere | Nov 2009 | A1 |
20090292307 | Razack | Nov 2009 | A1 |
20090299393 | Martin et al. | Dec 2009 | A1 |
20090299403 | Chanduszko et al. | Dec 2009 | A1 |
20090306702 | Miloslavski et al. | Dec 2009 | A1 |
20090326636 | Hashimoto et al. | Dec 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100076482 | Shu et al. | Mar 2010 | A1 |
20100087850 | Razack | Apr 2010 | A1 |
20100087908 | Hilaire et al. | Apr 2010 | A1 |
20100114017 | Lenker et al. | May 2010 | A1 |
20100125326 | Kalstad et al. | May 2010 | A1 |
20100125327 | Agnew | May 2010 | A1 |
20100191272 | Keating | Jul 2010 | A1 |
20100211094 | Sargent, Jr. | Aug 2010 | A1 |
20100268264 | Bonnette et al. | Oct 2010 | A1 |
20100268265 | Krolik et al. | Oct 2010 | A1 |
20100274277 | Eaton | Oct 2010 | A1 |
20100318178 | Rapaport et al. | Dec 2010 | A1 |
20100324649 | Mattsson et al. | Dec 2010 | A1 |
20100331949 | Habib | Dec 2010 | A1 |
20110009875 | Grandfield et al. | Jan 2011 | A1 |
20110009940 | Grandfield et al. | Jan 2011 | A1 |
20110009950 | Grandfield et al. | Jan 2011 | A1 |
20110015718 | Schreck | Jan 2011 | A1 |
20110022149 | Cox et al. | Jan 2011 | A1 |
20110040319 | Fulton, III | Feb 2011 | A1 |
20110054287 | Schultz | Mar 2011 | A1 |
20110054504 | Porter | Mar 2011 | A1 |
20110054514 | Arcand et al. | Mar 2011 | A1 |
20110054516 | Keegan et al. | Mar 2011 | A1 |
20110060212 | Slee et al. | Mar 2011 | A1 |
20110060359 | Hannes et al. | Mar 2011 | A1 |
20110106137 | Shimon | May 2011 | A1 |
20110125181 | Brady et al. | May 2011 | A1 |
20110152920 | Eckhouse et al. | Jun 2011 | A1 |
20110160763 | Ferrera et al. | Jun 2011 | A1 |
20110166586 | Sepetka et al. | Jul 2011 | A1 |
20110184456 | Grandfield et al. | Jul 2011 | A1 |
20110196414 | Porter et al. | Aug 2011 | A1 |
20110202088 | Eckhouse et al. | Aug 2011 | A1 |
20110208233 | McGuckin, Jr. et al. | Aug 2011 | A1 |
20110213297 | Aklog et al. | Sep 2011 | A1 |
20110213393 | Aklog et al. | Sep 2011 | A1 |
20110213403 | Aboytes | Sep 2011 | A1 |
20110224707 | Miloslavski et al. | Sep 2011 | A1 |
20110270374 | Orr et al. | Nov 2011 | A1 |
20110276120 | Gilson et al. | Nov 2011 | A1 |
20110319917 | Ferrera et al. | Dec 2011 | A1 |
20120022572 | Braun et al. | Jan 2012 | A1 |
20120041449 | Eckhouse et al. | Feb 2012 | A1 |
20120041469 | Fischell et al. | Feb 2012 | A1 |
20120041474 | Eckhouse et al. | Feb 2012 | A1 |
20120059356 | di Palma et al. | Mar 2012 | A1 |
20120065660 | Ferrera et al. | Mar 2012 | A1 |
20120083823 | Shrivastava et al. | Apr 2012 | A1 |
20120083868 | Shrivastava et al. | Apr 2012 | A1 |
20120089216 | Rapaport et al. | Apr 2012 | A1 |
20120101510 | Lenker et al. | Apr 2012 | A1 |
20120116440 | Leynov et al. | May 2012 | A1 |
20120123466 | Porter et al. | May 2012 | A1 |
20120143230 | Sepetka et al. | Jun 2012 | A1 |
20120143237 | Cam et al. | Jun 2012 | A1 |
20120143317 | Cam et al. | Jun 2012 | A1 |
20120150147 | Leynov et al. | Jun 2012 | A1 |
20120165858 | Eckhouse et al. | Jun 2012 | A1 |
20120165859 | Eckhouse et al. | Jun 2012 | A1 |
20120209312 | Aggerholm et al. | Aug 2012 | A1 |
20120215250 | Grandfield et al. | Aug 2012 | A1 |
20120277788 | Cattaneo | Nov 2012 | A1 |
20120283768 | Cox et al. | Nov 2012 | A1 |
20120296362 | Cam et al. | Nov 2012 | A1 |
20120316600 | Ferrera et al. | Dec 2012 | A1 |
20120330350 | Jones et al. | Dec 2012 | A1 |
20130030460 | Marks et al. | Jan 2013 | A1 |
20130030461 | Marks et al. | Jan 2013 | A1 |
20130046330 | McIntosh et al. | Feb 2013 | A1 |
20130046333 | Jones et al. | Feb 2013 | A1 |
20130046334 | Jones et al. | Feb 2013 | A1 |
20130116774 | Strauss et al. | May 2013 | A1 |
20130131614 | Hassan et al. | May 2013 | A1 |
20130144311 | Fung et al. | Jun 2013 | A1 |
20130144326 | Brady et al. | Jun 2013 | A1 |
20130158591 | Koehler | Jun 2013 | A1 |
20130158592 | Porter | Jun 2013 | A1 |
20130184739 | Brady et al. | Jul 2013 | A1 |
20130197567 | Brady et al. | Aug 2013 | A1 |
20130226146 | Tekulve | Aug 2013 | A1 |
20130268050 | Wilson et al. | Oct 2013 | A1 |
20130281788 | Garrison | Oct 2013 | A1 |
20130325051 | Martin et al. | Dec 2013 | A1 |
20130325055 | Eckhouse et al. | Dec 2013 | A1 |
20130325056 | Eckhouse et al. | Dec 2013 | A1 |
20130325107 | Wu | Dec 2013 | A1 |
20130345739 | Brady et al. | Dec 2013 | A1 |
20140005712 | Martin | Jan 2014 | A1 |
20140005713 | Bowman | Jan 2014 | A1 |
20140046359 | Bowman et al. | Feb 2014 | A1 |
20140088678 | Wainwright et al. | Mar 2014 | A1 |
20140121672 | Folk | May 2014 | A1 |
20140128905 | Molaei | May 2014 | A1 |
20140134654 | Rudel et al. | May 2014 | A1 |
20140135812 | Divino et al. | May 2014 | A1 |
20140142598 | Fulton, III | May 2014 | A1 |
20140163367 | Eskuri | Jun 2014 | A1 |
20140180122 | Stigall et al. | Jun 2014 | A1 |
20140180377 | Bose et al. | Jun 2014 | A1 |
20140180397 | Gerberding et al. | Jun 2014 | A1 |
20140194911 | Johnson et al. | Jul 2014 | A1 |
20140194919 | Losordo et al. | Jul 2014 | A1 |
20140200607 | Sepetka et al. | Jul 2014 | A1 |
20140200608 | Brady et al. | Jul 2014 | A1 |
20140236220 | Inoue | Aug 2014 | A1 |
20140243881 | Lees et al. | Aug 2014 | A1 |
20140257362 | Eidenschink | Sep 2014 | A1 |
20140276922 | McLain et al. | Sep 2014 | A1 |
20140277079 | Vale et al. | Sep 2014 | A1 |
20140303667 | Cox et al. | Oct 2014 | A1 |
20140309657 | Ben-Ami | Oct 2014 | A1 |
20140309673 | Dacuycuy et al. | Oct 2014 | A1 |
20140330302 | Tekulve et al. | Nov 2014 | A1 |
20140343585 | Ferrera et al. | Nov 2014 | A1 |
20140371769 | Vale et al. | Dec 2014 | A1 |
20140371779 | Vale et al. | Dec 2014 | A1 |
20140371780 | Vale et al. | Dec 2014 | A1 |
20140379023 | Brady et al. | Dec 2014 | A1 |
20150018859 | Quick et al. | Jan 2015 | A1 |
20150018860 | Quick et al. | Jan 2015 | A1 |
20150032144 | Holloway | Jan 2015 | A1 |
20150080937 | Davidson | Mar 2015 | A1 |
20150112376 | Molaei et al. | Apr 2015 | A1 |
20150133990 | Davidson | May 2015 | A1 |
20150150672 | Ma | Jun 2015 | A1 |
20150164523 | Brady et al. | Jun 2015 | A1 |
20150224133 | Ohri et al. | Aug 2015 | A1 |
20150250497 | Marks et al. | Sep 2015 | A1 |
20150257775 | Gilvarry et al. | Sep 2015 | A1 |
20150272716 | Pinchuk et al. | Oct 2015 | A1 |
20150297252 | Miloslavski et al. | Oct 2015 | A1 |
20150313617 | Grandfield et al. | Nov 2015 | A1 |
20150320431 | Ulm | Nov 2015 | A1 |
20150352325 | Quick | Dec 2015 | A1 |
20150359547 | Vale et al. | Dec 2015 | A1 |
20150366650 | Zi et al. | Dec 2015 | A1 |
20150374391 | Quick et al. | Dec 2015 | A1 |
20150374393 | Brady et al. | Dec 2015 | A1 |
20150374479 | Vale | Dec 2015 | A1 |
20160015402 | Brady et al. | Jan 2016 | A1 |
20160022296 | Brady et al. | Jan 2016 | A1 |
20160045298 | Thinnes, Jr. et al. | Feb 2016 | A1 |
20160066921 | Seifert et al. | Mar 2016 | A1 |
20160100928 | Lees et al. | Apr 2016 | A1 |
20160106448 | Brady et al. | Apr 2016 | A1 |
20160106449 | Brady et al. | Apr 2016 | A1 |
20160113663 | Brady et al. | Apr 2016 | A1 |
20160113664 | Brady et al. | Apr 2016 | A1 |
20160113665 | Brady et al. | Apr 2016 | A1 |
20160120558 | Brady et al. | May 2016 | A1 |
20160143653 | Vale et al. | May 2016 | A1 |
20160192953 | Brady et al. | Jul 2016 | A1 |
20160192954 | Brady et al. | Jul 2016 | A1 |
20160192955 | Brady et al. | Jul 2016 | A1 |
20160192956 | Brady et al. | Jul 2016 | A1 |
20160256180 | Vale et al. | Sep 2016 | A1 |
20160303381 | Pierce et al. | Oct 2016 | A1 |
20160317168 | Brady et al. | Nov 2016 | A1 |
20170007264 | Cruise et al. | Jan 2017 | A1 |
20170007265 | Guo et al. | Jan 2017 | A1 |
20170020542 | Martin et al. | Jan 2017 | A1 |
20170020670 | Murray et al. | Jan 2017 | A1 |
20170020700 | Bienvenu et al. | Jan 2017 | A1 |
20170027640 | Kunis et al. | Feb 2017 | A1 |
20170027692 | Bonhoeffer et al. | Feb 2017 | A1 |
20170027725 | Argentine | Feb 2017 | A1 |
20170035436 | Morita | Feb 2017 | A1 |
20170035567 | Duffy | Feb 2017 | A1 |
20170042548 | Lam | Feb 2017 | A1 |
20170049596 | Schabert | Feb 2017 | A1 |
20170056061 | Ogle et al. | Mar 2017 | A1 |
20170071614 | Vale et al. | Mar 2017 | A1 |
20170071737 | Kelley | Mar 2017 | A1 |
20170072452 | Monetti et al. | Mar 2017 | A1 |
20170079671 | Morero et al. | Mar 2017 | A1 |
20170079680 | Bowman | Mar 2017 | A1 |
20170079766 | Wang et al. | Mar 2017 | A1 |
20170079767 | Leon-Yip | Mar 2017 | A1 |
20170079812 | Lam et al. | Mar 2017 | A1 |
20170079817 | Sepetka et al. | Mar 2017 | A1 |
20170079819 | Pung et al. | Mar 2017 | A1 |
20170079820 | Lam et al. | Mar 2017 | A1 |
20170086851 | Wallace et al. | Mar 2017 | A1 |
20170086862 | Vale et al. | Mar 2017 | A1 |
20170086863 | Brady et al. | Mar 2017 | A1 |
20170086996 | Peterson et al. | Mar 2017 | A1 |
20170095259 | Tompkins et al. | Apr 2017 | A1 |
20170100126 | Bowman et al. | Apr 2017 | A1 |
20170100141 | Morero et al. | Apr 2017 | A1 |
20170100143 | Grandfield | Apr 2017 | A1 |
20170100183 | Iaizzo et al. | Apr 2017 | A1 |
20170105743 | Vale et al. | Apr 2017 | A1 |
20170112515 | Brady et al. | Apr 2017 | A1 |
20170112647 | Sachar et al. | Apr 2017 | A1 |
20170113023 | Steingisser et al. | Apr 2017 | A1 |
20170119409 | Ma | May 2017 | A1 |
20170143465 | Ulm, III | May 2017 | A1 |
20170147765 | Mehta | May 2017 | A1 |
20170150979 | Ulm | Jun 2017 | A1 |
20170151032 | Loisel | Jun 2017 | A1 |
20170165062 | Rothstein | Jun 2017 | A1 |
20170165065 | Rothstein et al. | Jun 2017 | A1 |
20170165454 | Tuohy et al. | Jun 2017 | A1 |
20170172581 | Bose et al. | Jun 2017 | A1 |
20170172766 | Vong et al. | Jun 2017 | A1 |
20170172772 | Khenansho | Jun 2017 | A1 |
20170189033 | Sepetka et al. | Jul 2017 | A1 |
20170189035 | Porter | Jul 2017 | A1 |
20170189041 | Cox et al. | Jul 2017 | A1 |
20170215902 | Leynov et al. | Aug 2017 | A1 |
20170216484 | Cruise et al. | Aug 2017 | A1 |
20170224350 | Shimizu et al. | Aug 2017 | A1 |
20170224355 | Bowman et al. | Aug 2017 | A1 |
20170224467 | Piccagli et al. | Aug 2017 | A1 |
20170224511 | Dwork et al. | Aug 2017 | A1 |
20170224953 | Tran et al. | Aug 2017 | A1 |
20170231749 | Perkins et al. | Aug 2017 | A1 |
20170252064 | Staunton | Sep 2017 | A1 |
20170265983 | Lam et al. | Sep 2017 | A1 |
20170281192 | Tieu et al. | Oct 2017 | A1 |
20170281331 | Perkins et al. | Oct 2017 | A1 |
20170281344 | Costello | Oct 2017 | A1 |
20170281909 | Northrop et al. | Oct 2017 | A1 |
20170281912 | Melder et al. | Oct 2017 | A1 |
20170290593 | Cruise et al. | Oct 2017 | A1 |
20170290654 | Sethna | Oct 2017 | A1 |
20170296324 | Argentine | Oct 2017 | A1 |
20170296325 | Marrocco et al. | Oct 2017 | A1 |
20170303939 | Greenhalgh et al. | Oct 2017 | A1 |
20170303942 | Greenhalgh et al. | Oct 2017 | A1 |
20170303947 | Greenhalgh et al. | Oct 2017 | A1 |
20170303948 | Wallace et al. | Oct 2017 | A1 |
20170304041 | Argentine | Oct 2017 | A1 |
20170304097 | Corwin et al. | Oct 2017 | A1 |
20170304595 | Nagasrinivasa et al. | Oct 2017 | A1 |
20170312109 | Le | Nov 2017 | A1 |
20170312484 | Shipley et al. | Nov 2017 | A1 |
20170316561 | Helm et al. | Nov 2017 | A1 |
20170319826 | Bowman et al. | Nov 2017 | A1 |
20170333228 | Orth et al. | Nov 2017 | A1 |
20170333236 | Greenan | Nov 2017 | A1 |
20170333678 | Bowman et al. | Nov 2017 | A1 |
20170340383 | Bloom et al. | Nov 2017 | A1 |
20170348014 | Wallace et al. | Dec 2017 | A1 |
20170348514 | Guyon et al. | Dec 2017 | A1 |
20180140315 | Bowman et al. | May 2018 | A1 |
20180206865 | Martin et al. | Jul 2018 | A1 |
20180207399 | Chou et al. | Jul 2018 | A1 |
20180263650 | Iwanami et al. | Sep 2018 | A1 |
20180325537 | Shamay et al. | Nov 2018 | A1 |
20180326024 | Prochazka et al. | Nov 2018 | A1 |
20180344338 | Brady et al. | Dec 2018 | A1 |
20190000492 | Casey et al. | Jan 2019 | A1 |
20190015061 | Liebeskind et al. | Jan 2019 | A1 |
20190167284 | Friedman et al. | Jun 2019 | A1 |
20190239907 | Brady et al. | Aug 2019 | A1 |
20190292273 | Hanotin et al. | Sep 2019 | A1 |
20190374239 | Martin et al. | Dec 2019 | A1 |
20190380723 | Grandfield et al. | Dec 2019 | A1 |
20190388097 | Girdhar et al. | Dec 2019 | A1 |
20200000483 | Brady et al. | Jan 2020 | A1 |
20200009150 | Chamorro Sanchez | Jan 2020 | A1 |
20200085444 | Vale et al. | Mar 2020 | A1 |
20200100804 | Casey et al. | Apr 2020 | A1 |
20200297364 | Choe et al. | Sep 2020 | A1 |
20200390459 | Casey et al. | Dec 2020 | A1 |
20210005321 | Hwang | Jan 2021 | A1 |
20210007757 | Casey et al. | Jan 2021 | A1 |
20210228223 | Casey et al. | Jul 2021 | A1 |
20220192739 | Deen et al. | Jun 2022 | A1 |
Number | Date | Country |
---|---|---|
2557083 | Jun 2003 | CN |
101172051 | May 2008 | CN |
102307613 | Jan 2012 | CN |
102316809 | Jan 2012 | CN |
102596098 | Jul 2012 | CN |
103764049 | Apr 2014 | CN |
104042304 | Sep 2014 | CN |
105208950 | Dec 2015 | CN |
105662532 | Jun 2016 | CN |
205359559 | Jul 2016 | CN |
107530090 | Jan 2018 | CN |
208582467 | Mar 2019 | CN |
202009001951 | Mar 2010 | DE |
102009056450 | Jun 2011 | DE |
102010010849 | Sep 2011 | DE |
102010014778 | Oct 2011 | DE |
102010024085 | Dec 2011 | DE |
102011014586 | Sep 2012 | DE |
1153581 | Nov 2001 | EP |
2301450 | Mar 2011 | EP |
2438891 | Apr 2012 | EP |
2628455 | Aug 2013 | EP |
3156004 | Apr 2017 | EP |
3669802 | Dec 2019 | EP |
3593742 | Jan 2020 | EP |
3858291 | Aug 2021 | EP |
2210456 | Jul 2004 | ES |
2427554 | Jan 2007 | GB |
2494820 | Mar 2013 | GB |
09-19438 | Jan 1997 | JP |
2014-511223 | May 2014 | JP |
2014-525796 | Oct 2014 | JP |
2015-505250 | Feb 2015 | JP |
2016-513505 | May 2016 | JP |
2019-526365 | Sep 2019 | JP |
2019-536552 | Dec 2019 | JP |
WO 9424926 | Nov 1994 | WO |
WO 9727808 | Aug 1997 | WO |
WO 9738631 | Oct 1997 | WO |
WO 9920335 | Apr 1999 | WO |
WO 9956801 | Nov 1999 | WO |
WO 9960933 | Dec 1999 | WO |
WO 0121077 | Mar 2001 | WO |
WO 0202162 | Jan 2002 | WO |
WO 0211627 | Feb 2002 | WO |
WO 0243616 | Jun 2002 | WO |
WO 02070061 | Sep 2002 | WO |
WO 02094111 | Nov 2002 | WO |
WO 03002006 | Jan 2003 | WO |
WO 03030751 | Apr 2003 | WO |
WO 03051448 | Jun 2003 | WO |
WO 2004028571 | Apr 2004 | WO |
WO 2004056275 | Jul 2004 | WO |
WO 2005000130 | Jan 2005 | WO |
WO 2005027779 | Mar 2005 | WO |
WO 2006021407 | Mar 2006 | WO |
WO 2006031410 | Mar 2006 | WO |
WO 2006107641 | Oct 2006 | WO |
WO 2006135823 | Dec 2006 | WO |
WO 2007054307 | May 2007 | WO |
WO 2007068424 | Jun 2007 | WO |
WO 2008034615 | Mar 2008 | WO |
WO 2008051431 | May 2008 | WO |
WO 2008131116 | Oct 2008 | WO |
WO 2008135823 | Nov 2008 | WO |
WO 2009031338 | Mar 2009 | WO |
WO 2009076482 | Jun 2009 | WO |
WO 2009086482 | Jul 2009 | WO |
WO 2009105710 | Aug 2009 | WO |
WO 2010010545 | Jan 2010 | WO |
WO 2010046897 | Apr 2010 | WO |
WO 2010075565 | Jul 2010 | WO |
WO 2010102307 | Sep 2010 | WO |
WO 2010146581 | Dec 2010 | WO |
WO 2011013556 | Feb 2011 | WO |
WO 2011066961 | Jun 2011 | WO |
WO 2011082319 | Jul 2011 | WO |
WO 2011095352 | Aug 2011 | WO |
WO 2011106426 | Sep 2011 | WO |
WO 2011110316 | Sep 2011 | WO |
WO 2011135556 | Nov 2011 | WO |
WO 2012052982 | Apr 2012 | WO |
WO 2012064726 | May 2012 | WO |
WO 2012081020 | Jun 2012 | WO |
WO 2012110619 | Aug 2012 | WO |
WO 2012120490 | Sep 2012 | WO |
WO 2012156924 | Nov 2012 | WO |
WO 2013016435 | Jan 2013 | WO |
WO 2013072777 | May 2013 | WO |
WO 2013105099 | Jul 2013 | WO |
WO 2013109756 | Jul 2013 | WO |
WO 2013187927 | Dec 2013 | WO |
WO 2014047650 | Mar 2014 | WO |
WO 2014081892 | May 2014 | WO |
WO 2014139845 | Sep 2014 | WO |
WO 2014169266 | Oct 2014 | WO |
WO 2014178198 | Nov 2014 | WO |
WO 2015061365 | Apr 2015 | WO |
WO 2015103547 | Jul 2015 | WO |
WO 2015134625 | Sep 2015 | WO |
WO 2015179324 | Nov 2015 | WO |
WO 2015189354 | Dec 2015 | WO |
WO 2016010995 | Jan 2016 | WO |
WO 2016089451 | Jun 2016 | WO |
WO 2017089424 | Jun 2017 | WO |
WO 2017090473 | Jun 2017 | WO |
WO 2017103686 | Jun 2017 | WO |
WO 2017161204 | Sep 2017 | WO |
WO 2020039082 | Feb 2020 | WO |
WO 2021113302 | Jun 2021 | WO |
Entry |
---|
US 6,348,062 B1, 02/2002, Hopkins et al. (withdrawn) |
Number | Date | Country | |
---|---|---|---|
20230355258 A1 | Nov 2023 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16946362 | Jun 2020 | US |
Child | 18218230 | US |